NCT05563480 2026-04-07
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
Clinical Trials
25 trialsNCT07381075 2026-02-02
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT05807880 2026-01-23
ALTER-HN005
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT06341530 2024-04-02
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05028504 2023-12-27
ALTER-GO-020
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06114225 2023-11-02
PROMIS
Ruijin Hospital
Phase 2 Recruiting
NCT06081673 2023-10-13
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT06051851 2023-09-25
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05885399 2023-06-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05726175 2023-02-13
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05519202 2022-08-29
Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer
The Central Hospital of Lishui City
Phase 2 Unknown
NCT05485350 2022-08-03
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Peking University Third Hospital
Phase 2 Unknown
NCT05460481 2022-07-20
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
Hunan Cancer Hospital
Phase 2 Unknown
NCT05244993 2022-07-12
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04952493 2022-01-28
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05137171 2021-11-30
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown